IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ImmunityBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$8.42−0.76 (-8.28%)
Close on Oct 19, 2026
- Market cap
- $8.84B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$6.02 (+250.8%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ImmunityBio, Inc. grew revenue 192.9% to $165.79M over the twelve months to Jun 30, 2026. Free cash flow was -$288.07M.
Revenue
$165.79M
+192.9% vs. a year earlier
Operating income
-$251.80M
TTM Q2 2026
Free cash flow
-$288.07M
TTM Q2 2026
EPS, diluted
-$0.97
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $8.84B
- P/E ratio
- –
- Price to sales
- 53.33
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -3.26%
Fundamentals
- Revenue
- $165.79M
- Net income
- -$992.36M
- EPS, diluted
- -$0.97
- Free cash flow
- -$288.07M
- Book value per share
- -$1.00
- Diluted shares
- 1.05B
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$165.79M+192.9% YoY
Gross profit
$164.70M+192.0% YoY
Operating income
-$251.80M
Net income
-$992.36M
EPS, diluted
-$0.97
Free cash flow
-$288.07M
Reported periodTrailing twelve months